Ramsay Generale dente (XPAR:GDS) Research & Development: €0 Mil (TTM As of Dec. 2025)


XPAR:GDS Ramsay Generale de Sante SA XPAR:GDS
71 GF Score
Price €11.30
GF Value €21.72
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Ramsay Generale dente Research & Development?

Ramsay Generale dente XPAR:GDS -1.31% 71 Research & Development is €0 Mil as of Dec. 2025. GuruFocus rates XPAR:GDS with a GF Score™ of 71/100 and a GF Value™ of €21.72 (Possible Value Trap). The stock has 8 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Ramsay Generale dente's Research & Development for the three months ended in Dec. 2025 was €0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0 Mil.

Ramsay Generale dente  (XPAR:GDS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Ramsay Generale dente Research & Development Related Terms

Ramsay Generale dente Research & Development Historical Data

* Premium members only.

The historical data trend for Ramsay Generale dente's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ramsay Generale dente Research & Development Chart

Ramsay Generale dente Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ramsay Generale dente Quarterly Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XPAR:GDS
71GF Score
Ramsay Generale de Sante SA XPAR:GDS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ramsay Generale dente Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0 Mil mean?
Ramsay Generale dente (XPAR:GDS) has a Research & Development of €0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Ramsay Generale dente and its competitors.
Is Ramsay Generale dente's Research & Development too high?
Ramsay Generale dente's current Research & Development is €0 Mil. Overall, Ramsay Generale dente has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ramsay Generale dente's Research & Development compare to HCA and THC?
Ramsay Generale dente's Research & Development of €0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Ramsay Generale dente and its competitors. Ramsay Generale dente's current Research & Development is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ramsay Generale dente stock overvalued right now?
Based on GuruFocus' analysis, Ramsay Generale dente (XPAR:GDS) is currently considered Possible Value Trap. The stock's GF Value™ is €21.72, compared to a current price of €11.30 — trading 48% below its estimated fair value. The current Research & Development is €0 Mil. Ramsay Generale dente's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Ramsay Generale dente (XPAR:GDS), the current Research & Development is €0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ramsay Generale dente (XPAR:GDS) Overvalued in 2026?

Based on GuruFocus' analysis, Ramsay Generale dente stock appears to be undervalued. The current stock price of €11.30 is trading 48% below its estimated GF Value™ of €21.72. GuruFocus considers Ramsay Generale dente to be Possible Value Trap.

Key valuation signals for XPAR:GDS:

  • Research & Development: €0 Mil
  • GF Value™: €21.72 vs. price of €11.30 (48% below fair value)
  • GF Score™: 71/100 with 8 warning signs

No single metric tells the full story. See the XPAR:GDS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ramsay Generale dente Business Description

Other Exchanges 0OD6:UKGD6:Germany
Address 39 Rue Mstislav, Rostropovitch, Paris, FRA, 75017
Ramsay Generale de Sante SA operates in the private healthcare sector in France. The company provides a comprehensive range of patient care services in thirteen business segments: Nouvelle Aquitaine, Bourgogne-Franche Comte, Brittany, Centre-Val de Loire, Hauts de France, Normandy, Provence Alpes Cote d'Azur, Ile de France, Auvergne-Rhone Alpes, Occitanie, Italy, Nordics, and Head Office. It generates maximum revenue from the Ile de France segment. The company also specializes in cardiology, heart surgery, digestive surgery, dermatology, urology, ophthalmology, vascular and endovascular surgery.
71GF Score

Get the complete analysis for XPAR:GDS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.30
Price
€21.72
GF Value